Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies […]